Wordt geladen...
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that co...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4206612/ https://ncbi.nlm.nih.gov/pubmed/25342987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014539183 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|